AnaptysBio Moves to Dismiss Tesaro's Breach Claim Ahead of July 2026 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Globenewswire
- Litigation Progress: AnaptysBio filed a motion in Delaware to dismiss Tesaro's breach of contract claim, with a trial scheduled for July 14-17, 2026, which could significantly impact Anaptys' future revenue streams.
- Royalty Rights: Under the Collaboration Agreement with Tesaro, Anaptys is entitled to royalties of up to 25% on Jemperli sales, making this revenue source critical for the company's financial health.
- Legal Strategy: Anaptys argues that its motion aligns with Delaware's anti-SLAPP law, aiming to prevent Tesaro's lawsuit from undermining its legal rights, demonstrating the company's proactive legal defense.
- Future Outlook: Anaptys plans to separate its biopharma operations from its royalty assets by the end of 2026, aiming to optimize investor portfolios and enhance strategic flexibility for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANAB
Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 71.33 USD with a low forecast of 50.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.850
Low
50.00
Averages
71.33
High
140.00
Current: 47.850
Low
50.00
Averages
71.33
High
140.00
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AnaptysBio Director Sells 3,900 Shares for $193,342.50
- Share Sale: On December 23, AnaptysBio Director J. Anthony Ware sold 3,900 shares at $49.58 each for a total of $193,342.50, reducing his direct holdings by 28.82% from 13,530 to 9,630 shares.
- Ownership Structure: All shares sold were directly held, with no involvement from indirect entities or derivative instruments, indicating Ware's continued economic alignment with the company as he retains 9,630 shares along with options for 126,085 shares and 6,030 restricted stock units.
- Market Performance: Over the past year, AnaptysBio's stock surged more than 260%, significantly outperforming the S&P 500's approximately 17% gain, reflecting strong performance and market confidence in the biotechnology sector.
- Financial Health: As of the end of Q3, AnaptysBio reported $256.7 million in cash and investments, with collaboration revenue rising to $76.3 million from $30 million a year earlier, showcasing the company's innovative capabilities in areas of high unmet medical need.
Continue Reading
AnaptysBio Director Sells 3,900 Shares for $193,342.50
- Ownership Reduction: AnaptysBio Director J. Anthony Ware executed an open-market sale of 3,900 shares for $193,342.50, reducing his direct holdings by 28.82%, indicating a significant adjustment in his personal investment portfolio within a single event.
- First Open-Market Sale: This transaction marks Ware's first open-market sale at AnaptysBio, with the previous five filings being administrative in nature, highlighting a notable shift in his holding strategy within the company.
- Market Performance Context: The sale occurred at a stock price of $50.04, following a remarkable 264.63% one-year return, suggesting that Ware chose to realize gains during a period of elevated valuation, reflecting his acknowledgment of the current market conditions.
- Economic Alignment Maintained: Despite the reduction in direct holdings, Ware retains 9,630 shares and has options for an additional 126,085 shares along with 6,030 restricted stock units, ensuring that his economic alignment with the company remains intact.
Continue Reading